Approved regulatory verdict
Evidence outlook
Approved: Neuroblastoma
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
track record: Partial signal
How the evidence outlook works ↗
Featured trials The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Neuroblastoma · approved · Featured evidence · 3 approved Featured evidence · 3
Competitive landscape No competitors sharing a mechanism or indication in the current universe.
Upcoming events (16 total) Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
2026 (5) November 2026 (1) Phase 3 Neuroblastoma Recruiting
Est. primary completion 2026-11 ·
NCT04221035 ·
CT.gov ↗ What to watch December 2026 (4) Phase 1 Neuroblastoma Active not recruiting
Est. primary completion 2026-12 ·
NCT02573896 ·
CT.gov ↗ What to watch Phase 1 Neuroblastoma Recruiting
Est. primary completion 2026-12 ·
NCT05400603 ·
CT.gov ↗ What to watch Phase 1/2 Neuroblastoma Active not recruiting
Est. primary completion 2026-12 ·
NCT04211675 ·
CT.gov ↗ What to watch Phase 3 Neuroblastoma Recruiting
Est. primary completion 2026-12-15 ·
NCT07375563 ·
CT.gov ↗ What to watch 2027 (1) March 2027 (1) Phase 1 High-risk GD2-Positive Ewing Sarcoma Not yet recruiting
Est. primary completion 2027-03-01 ·
NCT06839703 ·
CT.gov ↗ What to watch 2028 (3) November 2028 (1) Phase 2 Neuroblastoma Active not recruiting
Est. primary completion 2028-11 ·
NCT05421897 ·
CT.gov ↗ What to watch December 2028 (2) Phase 2 Neuroblastoma Recruiting
Est. primary completion 2028-12 ·
NCT06450041 ·
CT.gov ↗ What to watch Phase 2 Neuroblastoma Recruiting
Est. primary completion 2028-12-31 ·
NCT07318831 ·
CT.gov ↗ What to watch 2029 (2) September 2029 (1) Phase 1/2 Neuroblastoma Not yet recruiting
Est. primary completion 2029-09-30 ·
NCT07437963 ·
CT.gov ↗ What to watch December 2029 (1) Phase 3 Neuroblastoma Recruiting
Est. primary completion 2029-12-31 ·
NCT06172296 ·
CT.gov ↗ What to watch 2030 (4) July 2030 (1) Phase 1 Neuroblastoma Recruiting
Est. primary completion 2030-07-01 ·
NCT06485947 ·
CT.gov ↗ What to watch September 2030 (1) Phase 3 Neuroblastoma Recruiting
Est. primary completion 2030-09-30 ·
NCT03126916 ·
CT.gov ↗ What to watch December 2030 (2) Phase 1/2 Neuroblastoma Recruiting
Est. primary completion 2030-12-31 ·
NCT07334301 ·
CT.gov ↗ What to watch Phase 2 Neuroblastoma Not yet recruiting
Est. primary completion 2030-12-31 ·
NCT07261241 ·
CT.gov ↗ What to watch 2032 (1) December 2032 (1) Phase 1 Neuroblastoma Not yet recruiting
Est. primary completion 2032-12-31 ·
NCT07688252 ·
CT.gov ↗ What to watch See the full readout calendar ↗
All registered studies Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.
All indications (46) Neuroblastoma (40) Other / comorbidity (6)
Phase 3 (9) Phase 2/3 (1) Phase 2 (17) Phase 1/2 (6) Phase 1 (13) Appears in other studies (1)